Biotage AB has entered into an agreement to acquire all outstanding shares of CA-based PhyNexus, Inc., for $21.5 million. The acquisition expands Biotage’s separations business within the growing biomolecule arena. Biotage will be able to provide customers with an enabling automation platform based on Dual Flow Chromatography and patented tip technology for higher throughput purification of biomolecules such as proteins, plasmids and antibodies at the lab-scale.   PhyNexus predominantly ...